Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTB323 in Severe, Refractory Systemic Lupus Erythematosus
NCT05798117Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2023
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 5
01
Overview
A Phase 2 trial of rapcabtagene autoleucel in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by Novartis. Started Feb 2023; status: completed.
02
Drugs
rapcabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05798117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798117.